BTKi Therapy for MCL: ICML 2023
New Evidence With BTK Inhibitor Therapy in MCL From ICML 2023

Released: August 17, 2023

Catherine C. Coombs
Catherine C. Coombs, MD, MS
Toby A Eyre
Toby A Eyre, MBChB, MD

Activity

Progress
1
Course Completed

In this episode, Catherine C. Coombs, MD, and Toby Eyre, MBChB, MD, discuss key trials presented at ICML 2023 evaluating the use of BTK inhibitors in mantle cell lymphoma (MCL). The discussion includes analyses of:

  • Phase II trial of acalabrutinib with rituximab for older patients with untreated MCL
  • BRUIN: updated results of pirtobrutinib in covalent BTK inhibitor–pretreated MCL
  • IMCL-2015 GELTAMO: 5-year update ibrutinib for untreated indolent MCL